Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ormutivimab plus rabies vaccine vs HRIG plus rabies vaccine for durability of immunity
CTR20234249Phase 4Completed
- Sponsor
- North China Pharmaceutical Jintan Biotechnology
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ormutivimab in rabies, sponsored by North China Pharmaceutical Jintan Biotechnology. Started Dec 2023; status: completed.
02
Drugs
ormutivimab
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20234249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234249.